Drugs / amilo-5MER
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05857215 | Mar → Jul 2021 | inflammatory disease | Galmed Pharmaceuticals Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amilo-5MER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05857215 ↗ |
| Modality | Peptide | “amilo-5MER is a 5 amino acid synthetic peptide MTADV” NCT05857215 ↗ |
| Route | Subcutaneous | “Amilo-5MER solution for subcutaneous administration” NCT05857215 ↗ |